# Integrated Biosciences

> Integrated Biosciences is a Redwood City biotech founded in 2022 that fuses optogenetics, chemistry, and AI to discover small-molecule drugs for age-related diseases. Its optogenetic screening platform uses light to control cellular biology at millisecond and micron scale, generating clean data to train an explainable-AI drug-discovery engine. The company has published in Nature - including a new structural class of antibiotics - and raised $17.2M in seed funding led by Sutter Hill Ventures.

- **Founded:** 2022
- **Headquarters:** Redwood City, California, United States
- **Founders:** Felix Wong (Co-Founder and CEO), Maxwell Wilson (Co-Founder), James J. Collins (Scientific Co-Founder, SAB Chair)
- **Team size:** ~18 employees
- **Products:** Optogenetic Screening Platform, Explainable AI Drug-Discovery Engine, Small-Molecule Therapeutics Pipeline
- **Notable:** Published a new structural class of small-molecule antibiotics in Nature (2023) - among the first new antibiotic classes in ~60 years and the first discovered via an explainable-AI platform., Raised $17.2M seed financing led by Sutter Hill Ventures (2024)., Unveiled a first-of-its-kind optogenetic screening platform for drug discovery (2025).

## Products & services

- **Optogenetic Screening Platform** — A first-of-its-kind drug-discovery platform that uses light to control biology with millisecond- and micron-level precision, unlocking previously intractable cellular targets and pathways.
- **Explainable AI Drug-Discovery Engine** — A proprietary AI platform trained on differentiated optogenetic datasets that identifies novel small-molecule drug candidates and explains why a molecule's structure matters.
- **Small-Molecule Therapeutics Pipeline** — A pipeline of novel small molecules aimed at age-related stress pathways and diseases, plus a demonstrated new structural class of antibiotics.

## Achievements

- Published a new structural class of small-molecule antibiotics in Nature (2023) - among the first new antibiotic classes in ~60 years and the first discovered via an explainable-AI platform.
- Raised $17.2M seed financing led by Sutter Hill Ventures (2024).
- Unveiled a first-of-its-kind optogenetic screening platform for drug discovery (2025).
- Assembled a scientific advisory board including Nobel laureate Sir David MacMillan and MIT's James J. Collins.
- Research featured in Nature, Nature Aging, and Cell Systems.

## Latest updates

- **2026-02** — Appointed Tony Wu and additional experts to the scientific advisory board.
- **2026-01** — Named Daniel J. Anderson, Ph.D. as Chief Scientific Officer.
- **2025-07** — Unveiled its first-of-its-kind optogenetic screening platform for drug discovery.
- **2024-10** — Closed $17.2M seed financing led by Sutter Hill Ventures.
- **2023-12** — Published a new class of AI-discovered antibiotics in Nature.

## Links

- Website: https://integratedbio.com
- LinkedIn: https://www.linkedin.com/company/integrated-biosciences-inc
- Twitter/X: https://x.com/Integrated_Bio

---

Profile page: https://yespress.io/integrated-biosciences-inc
Published by YesPress — https://yespress.io
Last updated: 2026-08-04